Compare URGN & PLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | URGN | PLAB |
|---|---|---|
| Founded | 2004 | 1969 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.8B |
| IPO Year | 2016 | 1995 |
| Metric | URGN | PLAB |
|---|---|---|
| Price | $43.68 | $29.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | $29.29 | ★ $44.33 |
| AVG Volume (30 Days) | 796.8K | ★ 1.5M |
| Earning Date | 05-06-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 9.09 |
| EPS | N/A | ★ 1.27 |
| Revenue | $1,128,000.00 | ★ $535,276,000.00 |
| Revenue This Year | $129.09 | $6.70 |
| Revenue Next Year | $70.96 | $4.96 |
| P/E Ratio | ★ N/A | $22.94 |
| Revenue Growth | N/A | ★ 18.77 |
| 52 Week Low | $15.86 | $20.05 |
| 52 Week High | $50.81 | $56.00 |
| Indicator | URGN | PLAB |
|---|---|---|
| Relative Strength Index (RSI) | 47.51 | 46.95 |
| Support Level | $42.00 | $27.65 |
| Resistance Level | $43.93 | $34.71 |
| Average True Range (ATR) | 1.98 | 1.78 |
| MACD | -0.60 | -0.12 |
| Stochastic Oscillator | 21.23 | 21.94 |
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
Photronics Inc is a U.S.-based company principally engaged in the manufacturing of photomasks, which are high-precision photographic quartz or glass plates containing microscopic images of electronic circuits. Photomasks are a key element in the manufacture of integrated circuits (ICs) and flat-panel displays (FPDs) and are used as masters to transfer circuit patterns onto semiconductor wafers and FPD substrates during fabrication, as well as to a lesser extent, other types of electrical and optical components. The Company has manufacturing facilities in Taiwan, China, South Korea, the United States, and Europe, and generates revenue globally, with Taiwan contributing the majority of total revenue.